Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBT Margin: 2010-2025

Historic EBT Margin for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -8,470.50%.

  • Northwest Biotherapeutics' EBT Margin fell 374193.00% to -8,470.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -7,838.42%, marking a year-over-year decrease of 347301.00%. This contributed to the annual value of -5,374.46% for FY2024, which is 223010.00% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its EBT Margin stood at -8,470.50% for Q3 2025, which was up 33.17% from -12,675.57% recorded in Q2 2025.
  • Northwest Biotherapeutics' EBT Margin's 5-year high stood at 1,025.93% during Q4 2021, with a 5-year trough of -12,675.57% in Q2 2025.
  • Over the past 3 years, Northwest Biotherapeutics' median EBT Margin value was -5,043.47% (recorded in 2025), while the average stood at -6,029.65%.
  • As far as peak fluctuations go, Northwest Biotherapeutics' EBT Margin soared by 42,657,356bps in 2021, and later plummeted by 892,165bps in 2025.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' EBT Margin stood at 1,025.93% in 2021, then tumbled by 427,535bps to -3,249.41% in 2022, then crashed by 43,238bps to -3,681.80% in 2023, then plummeted by 540,348bps to -9,085.28% in 2024, then tumbled by 374,193bps to -8,470.50% in 2025.
  • Its EBT Margin stands at -8,470.50% for Q3 2025, versus -12,675.57% for Q2 2025 and -5,043.47% for Q1 2025.